Change in management details | Change in treatment goals | Change in treatment modes | |||||
---|---|---|---|---|---|---|---|
Cancer type | Nontreatment to treatment | Treatment to nontreatment | Odds ratio† | Change in goal of original treatment plan | Change from treatment to supportive care or observation | Major change in type of treatment relative to plan before PET | Minor change in type of treatment relative to plan before PET |
Prostate | 25.3 | 9.7 | 4.3 | 12.9 | 13.7 | 8.5 | 12.1 |
Ovary | 34.2 | 7.2 | 3.1 | 12.5 | 19.2 | 6.4 | 19.2 |
Bladder | 29.9 | 8.0 | 4.0 | 15.7 | 13.8 | 9.1 | 26.7 |
Pancreas | 31.2 | 7.8 | 3.8 | 16.9 | 13.5 | 8.6 | 26.5 |
Stomach | 28.2 | 8.7 | 4.0 | 16.0 | 14.4 | 8.6 | 31.5 |
Small cell lung | 34.9 | 6.3 | 3.9 | 13.9 | 13.2 | 7.4 | 28.6 |
Kidney | 27.7 | 8.1 | 3.8 | 12.6 | 20.7 | 9.7 | 19.2 |
Uterus | 28.9 | 7.6 | 4.4 | 13.8 | 15.9 | 9.8 | 27.4 |
Myeloma | 41.7 | 7.0 | 2.2 | 11.7 | 20.3 | 5.3 | 9.7 |
Connective tissue | 29.7 | 6.7 | 4.9 | 12.4 | 11.8 | 10.1 | 29.0 |
Nonmelanoma skin | 25.5 | 5.9 | 7.7 | 10.0 | 8.9 | 5.1 | 31.7 |
Liver and intrahepatic bile ducts | 33.6 | 9.2 | 2.6 | 18.2 | 10.8 | 14.7 | 23.7 |
Cervix | 25.4 | 7.3 | 5.9 | 13.5 | 13.8 | 7.4 | 34.7 |
Gallbladder | 31.5 | 8.2 | 3.5 | 17.8 | 12.6 | 10.4 | 22.1 |
Other female genital | 30.0 | 7.1 | 4.5 | 15.1 | 7.3 | 8.3 | 34.5 |
Thyroid | 26.4 | 9.2 | 3.8 | 14.7 | 16.1 | 11.5 | 26.0 |
All other | 27.6 | 9.0 | 3.7 | 14.5 | 20.0 | 8.9 | 22.6 |
Total | 30.0 | 8.0 | 3.9 | 14.1 | 15.1 | 8.6 | 23.3 |
↵* Specific cancer types are listed when there were at least 500 cases for initial staging, restaging, and detection of suspected recurrence combined.
↵† Odds ratios compare chance of having plan for treatment after PET with chance of having plan for treatment before PET. Because more participants had treatment plans after PET than before PET, values were consistently higher than one.
Except for odds ratios, data are reported as percentages of cases.